Navigation Links
ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
Date:10/11/2011

LONDON, Oct. 11, 2011 /PRNewswire/ -- ViiV Healthcare announces the start of the Phase III MODERN Study [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen], also known as A4001095, comparing its CCR5-inhibitor, Celsentri/Selzentry® (maraviroc), to emtricitabine/tenofovir (Truvada®), both in combination with darunavir/ritonavir. The 96-week trial will evaluate a two-drug versus three-drug once-daily regimen for the treatment of antiretroviral-naive patients infected with CCR5-tropic HIV-1.

"The treatment of HIV has come a long way, but it is essential that we continue to pursue effective novel treatment strategies that minimise toxicity while maximising tolerability and convenience. The MODERN study will investigate a treatment approach using Celsentri that is designed to meet those goals," said Dr. John Pottage, Chief Scientific and Medical Officer, ViiV Healthcare. "ViiV Healthcare is committed to understanding patient needs and addressing them through innovative treatment approaches that directly reflect what we learn."

Exploration of HIV treatment regimens that don't include a nucleoside reverse transcriptase inhibitor (NRTI), currently recommended as part of standard of care for first line HIV therapy, continues to be an area of interest because of the potential to alleviate some long-term toxicities associated with NRTI-based regimens and preserve future treatment options.  

About MODERNMODERN is a Phase III, 96-week, multi-center, randomised, double-blind, comparative study. It will include approximately 804 antiretroviral-naive patients infected with CCR5-tropic HIV-1 from over 250 sites in the E.U., U.S. and Australia. The primary endpoint for MODERN is the proportion of patients with HIV-1 RNA <50 copies/mL at week 48. Secondary objectives include the proportion of patients with HIV-1 RNA below the limits of assay detection at week 96; change in CD4+ and CD8+ cell counts through 48 an
'/>"/>

SOURCE ViiV Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services
2. Medicalbillersandcoders.com Offers Effective Ways to Combat Healthcare Fraud and Abuse in California, Florida, and Michigan
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. GNS Healthcare, Inc Collaborates with Nationally Ranked Hospital to Predict Adverse Drug Events and Hospital Readmissions
5. Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference
6. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
7. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
8. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
9. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
10. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
11. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... and 10th, 2009, at BioSquare Meeting ... March 17, 2009, at BioEurope in Italy ... Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing products for ... Executive Vice President for Corporate Development, will participate in a Panel ...
... in probiotics and artificial sweeteners partner to ... to bring innovation to baking aisleINDIANAPOLIS, March ... a Cleveland-based manufacturer of the patented probiotic ... with Heartland Sweeteners , an Indianapolis-based ...
... 100 Percent Purified Seawater Helps Users Breathe FreelyKENILWORTH, N.J., ... ) today announced the launch of AFRIN(R) PureSea(TM) Hydrating ... of 100 percent purified sea water. Available in the ... proven to cleanse nasal and sinus passages of mucus, ...
Cached Biology Technology:Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 3Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France 2Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France 3
(Date:12/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces it has ... Robbins for the 2015 International CES debut of ... Apollo Robbins will be at the NXT-ID booth ... of his famous theft techniques to visiting media and ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal ... that pinpoints fine-scale differences in genetic ancestry of individuals ... Since immigrants first arrived more than four ... has served as a meeting place for peoples ... and the ongoing mixing of peoples with African, European, ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a ... its PerformTek biometric technology to industry leaders such as ... accurate, clinically validated, biometric wearable products. These products will ... in Las Vegas . ... is accurate, flexible and robust – with the clinical ...
Breaking Biology News(10 mins):NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... The ancient "terror bird" Andalgalornis couldn,t fly, but ... hooked beak--in a fighting strategy reminiscent of boxer Muhammad Ali. ... hatchet-like jabs to take down its prey, according to results ... PLoS ONE . The study is the first ...
... , This release is available in Spanish ... have developed a new tool for improving the expression of ... the results will do the most good. Roger Thilmony, ... that the LP2 gene promoter can be used to direct ...
... widening of the Panama Canal currently underway has created a ... of environmentally sensitive Central American rain forest habitats. Dr. ... New York (CCNY), is leading a research effort that could ... relationships. "If you want to study biodiversity and conservation, ...
Cached Biology News:Ancient 'terror bird' used powerful beak to jab like boxer 2Ancient 'terror bird' used powerful beak to jab like boxer 3Ancient 'terror bird' used powerful beak to jab like boxer 4New genetic tool helps improve rice 2CCNY biologists study rainforest host-plant associations 2CCNY biologists study rainforest host-plant associations 3
... Disrupts biological cells for DNA isolation. ... well plates (includes 96 well plate ... lysis across the entire plate length ... Can be used for soil, ...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Biology Products: